Még nem toboroz
Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization
NCT07219862· Keck School of Medicine of USC· Forrás
Contact: Hayoun Lee, PhD
Még nem toboroz
Methamphetamine Use Disorder Support in Heart Failure Pilot Study
NCT07211724· University of Southern California· Forrás
Contact: Maxine W Stachel, MD
Toboroz
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
NCT06980038· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jacob S. Thomas (principal investigator)
Toboroz
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
NCT07068074· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Fumito Ito (principal investigator)
Toboroz
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
NCT07339254· University of Southern California· Forrás
Contact: Sandy Tran
Toboroz
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Koji Matsuo (principal investigator)
Toboroz
New Approach to Objectively Measure Social Engagement in Older Adults With Hearing Loss
NCT06781749· University of Southern California· Forrás
Contact: Janet Choi, MD, MPH
Toboroz
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012· 1/2. fázis· Pfizer· Forrás
Toboroz
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
NCT07061964· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Siamak Daneshmand (principal investigator)
Toboroz
Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD
NCT07186699· University of Southern California· Forrás
Contact: Sandy Tran
Toboroz
Evaluating a Lifestyle Intervention to Prevent Recurrence of Diabetic Foot Ulcers
NCT06487780· University of Southern California· Forrás
Contact: Tze-Woei Tan
Toboroz
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
NCT06992427· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Adam Garsa (principal investigator)
Toboroz
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Lauren A. Lukas (principal investigator)
Toboroz
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Jacek Pinski (principal investigator)
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Varsha Tulpule (principal investigator)
Toboroz
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
NCT06336902· 1. fázis· University of Southern California· Forrás
Contact: Charlean Ketchens, RN
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Toboroz
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Mark Agulnik (principal investigator)
Toboroz
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05896839· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Gino K. In (principal investigator)
Toboroz
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485· 3. fázis· Canadian Cancer Trials Group· Forrás
Contact: Joshua P. Schiff (principal investigator)
Toboroz
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Syma Iqbal (principal investigator)
Fut, nem toboroz
Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).
NCT06253923· 2. fázis· SHINKEI Therapeutics, Inc· Forrás
Toboroz
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
NCT06063486· 2. fázis· University of Southern California· Forrás
Contact: Christine Duran
Toboroz
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
NCT05711615· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: Mark Agulnik (principal investigator)
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· 2. fázis· Pfizer· Forrás
Toboroz
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
NCT05691465· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jacek Pinski (principal investigator)
Fut, nem toboroz
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT05836571· 2. fázis· National Cancer Institute LAO· Forrás
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Director Regulatory Affairs
Toboroz
Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
NCT06500169· University of Southern California· Forrás
Contact: George Salem, PhD
Toboroz
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT05372640· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: Robert Hsu (principal investigator)
Toboroz
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
NCT05600894· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Community Genetic Navigation Engagement Specialists to Increase Knowledge About Colorectal Cancer Genetics in Hispanic/Latino/a Communities
NCT07276048· University of Southern California· Forrás
Fut, nem toboroz
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT05411094· 1. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
NCT05432804· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Jacob S. Thomas (principal investigator)
Toboroz
Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
NCT06067295· University of Southern California· Forrás
Contact: Cheryl Kefauver, RN
Fut, nem toboroz
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Toboroz
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· 2. fázis· NRG Oncology· Forrás
Contact: Lauren A. Lukas (principal investigator)
Toboroz
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Syma Iqbal (principal investigator)
Fut, nem toboroz
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT04616248· 1. fázis· University of Southern California· Forrás
Fut, nem toboroz
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
NCT05198830· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Gino K. In (principal investigator)
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130· 1. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
NCT05333458· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Mark Agulnik (principal investigator)
Fut, nem toboroz
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT05111574· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05172258· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
NCT05019716· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Robert Hsu (principal investigator)
Showing 50 of 150.